human
bocaviru
parvoviru
associ
respiratori
tract
infect
rti
children
causal
relat
yet
confirm
develop
qualit
revers
transcript
pcr
detect
splice
mrna
determin
whether
mrna
correl
better
rti
dna
use
sampl
dnaposit
children
without
rti
evalu
test
realtim
revers
transcript
pcr
target
altern
splice
mrna
develop
mrna
detect
nasopharyng
aspir
children
rti
none
control
p
analyt
sensit
specif
test
good
data
support
hypothesi
may
caus
rti
propos
mrna
could
use
benefit
instead
dna
diagnost
target
h
uman
bocaviru
small
nonenvelop
viru
parvovirida
famili
discov
human
respiratori
sampl
viru
grow
standard
cell
line
diagnosi
mainli
base
dna
detect
pcr
detect
multipl
virus
dnaposit
airway
sampl
children
respiratori
tract
infect
rti
characterist
find
mani
studi
addit
mani
healthi
children
test
posit
dna
thu
whether
viru
actual
caus
rti
children
bystand
infect
debat
howev
shown
follow
factor
associ
rti
viremia
dnaemia
high
dna
load
nasopharyng
aspir
npa
monodect
dna
npa
addit
rti
dnaposit
children
associ
seroconvers
evid
support
causal
relat
rti
children
dnabas
pcr
test
seem
diagnos
infect
accur
propos
detect
mrna
measur
activ
transcrib
viru
may
better
method
main
object
studi
develop
qualit
revers
transcript
pcr
rtpcr
detect
splice
mrna
clarifi
whether
mrna
detect
may
correl
better
dna
detect
rti
children
npa
blood
sampl
group
children
without
rti
test
posit
dna
use
purpos
dnaposit
npa
sampl
ongo
project
rti
children
year
age
use
evalu
test
particular
npa
sampl
collect
admitt
children
depart
pediatr
st
olav
hospit
trondheim
univers
hospit
trondheim
norway
june
includ
blood
sampl
also
avail
children
sampl
store
dnaposit
npa
sampl
children
rti
median
age
month
rang
year
boy
classifi
either
lower
children
upper
children
rti
lrti
urti
lrti
diagnos
presenc
dyspnea
sign
lower
airway
obstruct
wheez
retract
andor
chest
roentgenogram
posit
result
infiltr
atelectasi
air
trap
urti
diagnos
rhiniti
pharyng
andor
otiti
media
found
without
sign
lrti
addit
children
rti
admit
winter
follow
occas
month
twentyeight
dnaposit
npa
sampl
collect
group
children
admit
elect
surgeri
exhibit
sign
symptom
rti
previou
week
children
includ
prospect
period
median
age
month
rang
year
boy
npa
sampl
patient
control
also
test
pcr
adenoviru
coronaviru
enteroviru
parechoviru
human
metapneumoviru
hmpv
influenza
b
virus
parainfluenza
viru
type
respiratori
syncyti
viru
rsv
rhinoviru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
pcr
inhous
realtim
assay
taqman
probe
roch
diagnost
basel
switzerland
analys
conduct
part
daili
laboratori
routin
perform
within
hour
sampl
collect
target
dna
pcr
nuclear
gene
pcr
describ
semiquantit
approach
chosen
cutoff
valu
copiesml
use
distinguish
high
low
dna
load
npa
develop
realtim
rtpcr
basi
taqman
technolog
roch
follow
primer
design
forward
posit
revers
posit
estim
pcr
product
span
splice
segment
posit
complet
genom
genbank
access
give
theoret
pcr
product
bp
altern
product
includ
short
segment
posit
yield
product
bp
figur
estim
base
vitro
studi
perform
chen
et
al
probe
target
untransl
region
upstream
nuclear
gene
follow
sequenc
posit
pcr
everi
sampl
also
run
without
revers
transcript
test
potenti
unspecif
reaction
viral
dna
theoret
pcr
product
dna
would
bp
length
long
amplif
realtim
pcr
normal
condit
total
dna
rna
extract
use
nuclisen
easymag
extractor
marci
letoil
franc
revers
transcript
carri
univers
riboclon
random
primer
promega
fitchburg
wi
usa
mmlv
revers
transcriptas
life
technolog
corp
carlsbad
ca
usa
min
follow
min
pcr
perform
cycl
amplif
effici
calcul
use
formula
slope
standard
curv
human
dna
pcr
specif
light
chain
gene
chromosom
use
amplif
control
nucleic
acid
extract
clinic
sampl
posit
rsv
use
cdna
control
make
sure
mrna
degrad
storag
use
rtpcr
detect
human
actin
mrna
emerg
infecti
diseas
wwwcdcgoveid
vol
rna
stabil
studi
use
clinic
npa
sampl
nucleic
acid
extract
easymag
extractor
four
clinic
npa
sampl
collect
within
previou
hour
store
day
nucleic
acid
extract
test
mrna
pcr
one
npa
sampl
store
room
temperatur
test
likewis
two
clinic
npa
sampl
frozen
thaw
time
extract
test
mrna
pcr
time
skip
save
npa
materi
furthermor
mrna
pcr
result
npa
sampl
store
year
compar
nucleic
acid
extract
sampl
store
equal
condit
period
done
determin
whether
stabil
rna
clinic
npa
sampl
ad
viru
transport
medium
compar
stabil
rna
nucleic
acid
extract
easymag
temperatur
rel
chang
rna
load
measur
compar
logarithm
transform
cycl
threshold
valu
ct
valu
obtain
experi
quantit
standard
realtim
mrna
pcr
made
clone
plasmid
life
technolog
corp
contain
pcr
product
amount
nucleic
acid
measur
serial
dilut
cover
rang
log
made
measur
analyt
sensit
mrna
pcr
analyt
specif
evalu
use
cdna
npa
sampl
posit
respiratori
agent
includ
studi
cdna
npa
sampl
contain
virus
reactiv
respiratori
tract
also
includ
ie
herp
simplex
viru
cytomegaloviru
epsteinbarr
viru
human
herp
viru
final
cdna
npa
sampl
posit
close
relat
parvoviru
cdna
fecal
sampl
posit
human
bocavirus
test
primer
probe
describ
kantola
et
al
use
detect
two
sampl
posit
agent
use
sampl
undergon
extract
within
hour
sampl
collect
sequenc
analysi
pcr
product
perform
use
bigdy
termin
cycl
sequenc
method
abi
prism
genet
analyz
appli
biosystem
foster
citi
ca
usa
statist
analysi
test
categor
variabl
student
test
continu
variabl
multipl
logist
regress
analysi
use
evalu
associ
detect
mrna
lrti
control
differ
age
sex
presenc
virus
among
casepati
control
report
odd
ratio
ci
correspond
p
valu
measur
strength
associ
analys
perform
use
ibm
spss
statist
version
spss
inc
chicago
il
usa
mrna
detect
dnaposit
npa
sampl
tabl
gel
electrophoresi
show
primarili
pcr
product
amplifi
size
bp
bp
figur
sequenc
analysi
show
splice
product
either
intron
cut
expect
schemat
illustr
figur
exact
product
size
bp
bp
direct
pcr
analysi
mrna
nucleic
acid
extract
without
initi
revers
transcript
neg
npa
sampl
remain
sampl
howev
weak
signal
detect
sampl
high
dna
load
rang
copiesml
copiesml
also
strongli
posit
mrna
pcr
cdna
synthesi
product
pcr
done
without
cdna
synthesi
sequenc
product
size
bp
sequenc
analysi
show
gap
differ
posit
lack
splice
site
characterist
data
shown
amplif
effici
mrna
pcr
calcul
basi
dilut
nucleic
acid
extract
cdna
measur
case
indic
high
effici
pcr
cdna
synthesi
data
shown
assay
report
rang
copiesml
copiesreact
copiesml
result
pcr
perform
dnase
treatment
posit
sampl
studi
result
mrna
pcr
neg
respiratori
agent
herpesvirus
parvovirus
test
mrna
load
npa
remain
stabl
day
room
temperatur
unalt
h
reduc
log
day
log
day
freez
thaw
npa
sampl
twice
affect
yield
reduc
log
npa
sampl
store
year
result
equal
nucleic
acid
extract
origin
sampl
mrna
pcr
result
nucleic
acid
extract
stabl
week
sampl
store
sampl
store
week
test
data
shown
first
compar
rate
posit
test
result
mrna
among
children
posit
result
dna
without
rti
one
fourth
patient
none
control
test
result
posit
mrna
previous
found
factor
dnaemia
high
dna
npa
monodect
dna
npa
associ
rti
children
present
studi
factor
strongli
associ
posit
test
result
mrna
tabl
close
relationship
dna
load
mrna
detect
npa
also
illustr
figur
rti
patient
neg
mrna
posit
respiratori
virus
twentyeight
children
infect
highli
pathogen
rsv
distribut
virus
commonli
codetect
shown
tabl
winter
sequenti
collect
sampl
dnaposit
children
made
possibl
gain
inform
chang
mrna
dna
time
one
children
boy
boy
cerebr
palsi
admit
bronchiol
admiss
dnaemia
analysi
npa
show
high
dna
load
monodect
dna
posit
mrna
pcr
result
recov
slowli
day
new
npa
sampl
taken
dna
load
still
high
result
mrna
pcr
neg
two
month
later
npa
still
posit
dna
neg
mrna
patient
two
boy
boy
includ
hmpv
followup
studi
npa
sampl
becam
posit
dna
week
hmpv
infect
diagnos
initi
sampl
neg
dna
clinic
condit
unalt
dna
appear
dna
load
reach
moder
level
boy
high
level
boy
boy
pcr
neg
mrna
consecut
npa
sampl
taken
day
apart
unfortun
blood
sampl
taken
boy
report
develop
robust
pcr
detect
splice
mrna
found
mrna
correl
significantli
better
rti
children
dna
indic
pcr
may
diagnos
infect
accur
pcr
dna
splice
process
specif
mrna
synthesi
use
primer
pair
span
intron
splice
viral
mrna
specif
detect
within
frame
familiar
robust
rtpcr
diagnost
techniqu
use
diagnos
parvoviru
dog
may
also
option
diagnos
infect
human
furthermor
detect
mrna
routin
use
diagnos
human
papillomaviru
infect
studi
diagnos
human
herpesviru
hiv
infect
howev
mrna
test
virus
base
either
specif
mrna
extract
nucleic
acid
sequencebas
amplif
technolog
pretreat
dnase
advantag
approach
pretreat
cdna
synthesi
need
procedur
perform
regular
rtpcr
standard
equip
easi
use
routin
laboratori
analyt
perform
test
good
high
analyt
specif
sensit
probe
target
chosen
detect
product
figur
therebi
maxim
analyt
sensit
probe
span
splice
segment
posit
would
altern
approach
ensur
specif
detect
mrna
splice
exact
locat
figur
howev
result
indic
high
specif
chosen
probe
develop
approach
previous
rna
molecul
believ
short
halfliv
rnase
may
present
everywher
easili
degrad
rna
recent
studi
howev
suggest
mrna
may
stabl
molecul
kept
origin
biolog
materi
found
mrna
content
npa
sampl
stabl
period
stabil
suggest
npa
sampl
kept
refriger
process
within
day
standard
laboratori
safe
use
mrna
test
sampl
strong
signal
mrna
test
weak
signal
detect
also
without
prior
cdna
synthesi
evok
question
whether
dna
could
give
falseposit
reaction
mrna
test
pcr
design
theoret
dna
product
would
bptoo
larg
amplif
occur
regular
realtim
pcr
reason
pcr
product
expect
result
recombin
event
gel
sequenc
analysi
show
product
differ
size
rang
bp
moreov
common
sequenc
profil
found
near
gap
junction
seem
locat
random
homolog
recombin
concentrationdepend
process
may
explain
phenomenon
occur
npa
sampl
extrem
high
level
dna
specul
pcr
product
might
subpopul
nonviabl
mutant
appear
viru
replic
highest
howev
specif
test
affect
happen
patient
high
viral
dna
load
strong
mrna
signal
addit
diagnost
test
method
may
use
gain
inform
transcript
vivo
data
confirm
previou
vitro
result
splice
pattern
end
genom
figur
evalu
mrna
test
abl
use
avail
clinic
sampl
children
without
rti
test
respiratori
agent
dna
npa
none
children
without
rti
detect
mrna
mrna
marker
activ
viral
transcript
find
indic
asymptomat
children
carri
inact
low
activ
strong
associ
found
activ
transcript
rti
children
support
hypothesi
may
caus
rti
hypothesi
support
associ
found
mrna
factor
dnaemia
high
dna
load
npa
monodect
dnaall
factor
strongli
relat
rti
children
addit
fact
mrna
frequent
detect
children
lrti
urti
indic
lrti
promin
manifest
infect
one
fourth
dnaposit
children
rti
detect
mrna
similar
find
recent
report
proencamodena
et
al
absenc
mrna
children
rti
may
indic
children
clinic
despit
posit
test
result
dna
inde
respiratori
virus
frequent
detect
among
children
neg
mrna
test
result
rsv
account
one
third
infect
previous
mention
strong
relat
dna
load
npa
mrna
illustr
figur
show
distinct
popul
littl
overlap
good
discrimin
mrnaposit
neg
sampl
achiev
cutoff
valu
dna
copiesml
suggest
clinic
purpos
mrna
accur
dna
diagnos
activ
infect
high
dna
load
copiesml
may
also
use
diagnosi
previous
found
persist
npa
mani
month
molecular
basi
persist
larg
unknown
recent
studi
given
evid
support
persist
circular
hbov
episom
npa
sampl
studi
neg
mrna
posit
dna
could
patient
past
infect
still
shed
viral
dna
boy
follow
winter
may
illustr
result
pcr
npa
sampl
boy
posit
hbov
mrna
short
period
day
coincid
acut
symptomat
infect
wherea
dna
persist
month
altern
hypothesi
might
sampl
neg
mrna
posit
dna
children
latent
infect
find
boy
follow
winter
may
support
hypothesi
dna
npa
appear
ongo
hmpv
infect
children
result
pcr
mrna
remain
neg
consecut
sampl
lack
detect
mrna
may
indic
play
role
infect
releas
latent
dna
cell
disrupt
inflamm
caus
hmpv
may
better
explan
longitudin
studi
includ
serolog
analys
need
studi
relationship
quadrupl
infect
common
percentag
within
column
may
therefor
add
